BayMed Venture Partners — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit K. Gupta(Executive Officer, Director)Omer Inan(Co-founder, Chief Scientific Officer)Andrew Carek(Co-founder, Chief Technical Officer)Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan, PhD(Co-founder, Chief Scientific Officer)in
Co-investorsBroadview VenturesCross-Border Impact VenturesLaerdal Million Lives FundOSF VenturesPortal InnovationsHatteras Venture Partners
Embolx is a commercial-stage medical device company developing microcatheters for arterial embolization procedures used to treat conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids.
HardwareHealthtechMedical DevicesSunnyvale, US
MICHAEL ALLEN(President & Chief Executive Officer)Michael P. Allen(Executive Officer, Director)Robert J.J. de Neve(Executive Officer, Director)Michael Allen(President & CEO)NORMAN GITIS(Director)PAUL ROGAN(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.